Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Biochim Biophys Acta. Author manuscript; available in PMC 2011 December 23.
Published in final edited form as:
PMCID: PMC3245720

Adenine Nucleotide Translocator 1 Deficiency Increases Resistance of Mouse Brain and Neurons to Excitotoxic Insults


The mitochondrial adenine nucleotide translocators (Ant) are bi-functional proteins that transport ADP and ATP across the mitochondrial inner membrane, and regulate the mitochondrial permeability transition pore (mtPTP) which initiates apoptosis. The mouse has three Ant isoforms: Ant1 expressed in heart, muscle, and brain; Ant2 expressed in all tissues but muscle; and Ant4 expressed primarily in testis. Ant1-deficient mice manifest muscle and heart but not brain pathology. Brain Ant1 is induced by stress, while Ant2 is not. Ant1-deficient mice are resistant to death induced by systemic exposure to the brain excitotoxin, kainic acid (KA), and their hippocampal and cortical neurons are significantly more resistant to neuronal death induced by glutamate, KA, and etoposide‥ The mitochondrial membrane potential of Ant1-deficient brain mitochondria is increased and the mtPTP is more resistance to Ca++ induced permeability transition. Hence, Ant1-deficiency may protect the brain from excitotoxicity by desensitizing the mtPTP and by blocking the pro-apoptotic induction of Ant1 by stress.

Keywords: Adenine nucleotide translocator, mitochondria, mitochondrial permeability transition, excitotoxicity, apoptosis


The mitochondrial adenine nucleotide translocator (Ant or ADP/ATP translocase) is the most abundant mitochondrial inner membrane protein whose primary function is to exchange ADP and ATP across the mitochondrial inner membrane [1]. Humans have three main ANTs plus a testis isoform, while mouse has two main isoforms, Ant1 and Ant2, plus a testis isoform, Ant4. In mouse, Ant1 is expressed in the skeletal muscle, heart, and brain, while Ant2 is expressed in all tissues except skeletal muscle[2][3][4][5][6][7].

The Ants interact with a multi-polypeptide complex which spans the mitochondrial inner and outer membranes, the mitochondrial permeability transition pore (mtPTP)[810]. While the Ants do not appear to provide the actual ion channels of the mtPTP, they play an important role in regulating the mtPTP in response to calcium and adenine nucleotides [11]

Mice in which the Ant1 gene (Ant1) is insertionally inactivated (Ant1-deficient mice) develop mitochondrial myopathy associated with ragged-red fibers and abnormal mitochondria and a hypertrophic cardiomyopathy [12]. The muscle of Ant1 −/− mice exhibit an induction of mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) oxidative phosphorylation (OXPHOS) gene expression, antioxidant defense proteins, and anti-apoptotic factors [13][14][15]. Yet, Ant1-deficient mice show no overt evidence of neurological disease.

To determine why the muscle and heart are affected in Ant1-deficient mice but the brain is not, we examined the response of Ant1-deficient mice to excitotoxic KA brain insult and Ant1-deficient cultured mouse neurons to excitotoxins (glutamate and KA) and the DNA damaging agent (etoposide). Ant1-deficient mice were as prone as wild type mice to KA induced seizures, but were more resistant to KA-induced death. Ant1-deficient neurons were resistant to glutamate and KA induced death and their mitochondria had increased membrane potential, decreased ATP, and partially stabilized mtPTP. These results suggest that the loss of Ant1 stabilizes the mtPTP against Ca++ activation. Therefore, Ant1-deficient mice may be resistant to neurodegeneration because the mtPTPs of their neurons are less prone to permeability transition and to stress-induced induction of Ant1 and initiation of apoptosis.


Ant1-Deficient Mice, Brain Expression of Ants, and Kainic Acid Toxicity

Mice and Mouse Handling

Ant1-deficient mice on C57BL/6J2z background were previously prepared by the insertional inactivation of the Ant1 gene by in-frame insertion of the βgeo cassette encompassing a β-galactosidase-neomycin fusion protein (βgeo) [12]. Mice were maintained at 20–23°C on a 13-hr light/11-hr dark cycle using the procedures mandated by the National Institutes of Health guidelines and the University of California Institutional Animal Care and Use Committee.

Regional Brain Expression of Ant1

The regional expression of Ant1 was investigated by staining brain sections of heterozygous Ant1βgeo mice for expression of β-galactosidase transcribed from the Ant1 gene promoter [12]. Mouse brains were serially cryostat sectioned (15 µm) in either the coronal or the sagittal plane, the sections fixed in 2% formaldehyde and 1% glutaraldehyde in saline buffer, the sections rinsed and stained with X-gal solution for 24 hours at 37°C, and then counterstained with Nuclear Fast Red [16].

Kainic Acid Excitotoxicity

The tendency of Ant1-deficient and control mice to develop seizures and to die in response to the brain excitotoxic agent kainic KA was investigated by a single intraperitoneal injection of 35 mg/kg KA into age-matched Ant1-deficient and control animals. Mice were then monitored continuously for 3–4 h. At 2 hours they were evaluated for the onset and extent of seizure activity and animal survival. Seizure activity was rated as immobility, stage 1; forelimb and/or tail extension and rigid posture, stage 2; repetitive movements and head bobbing, stage 3; rearing and falling, stage 4; continuous rearing and falling, stage 5; severe tonic–clonic seizures, stage 6 [17]. Survival was assessed at 2 and 48 hours.

Western Blot Analysis of Ant1 and Ant2 Protein Levels

Relative protein levels were assessed by Western blots prepared from 50 µg solubilized protein using as primary antibodies rabbit polyclonal antibodies against Ant1 and Ant2 [12], and a mouse porin 31HL monoclonal antibody (CalBiochem, 89–173/016; 1:10000 dilution). Western blots were immunoreacted with primary antibodies overnight at 4°C, stained with horse radish peroxidase (HRP)-conjugated secondary antibody (the species origin of the secondary antibodies varied depending on the origin of the primary antibody), the antibody staining detected by chemiluminescence (Amersham), and quantified by densitometric analysis.

Primary Neuronal Cell Cultures: Treatments and Cell Death

Preparation of Primary Neuronal Cultures

Primary mouse embryonic brain cell cultures were established from dissociated 18 day embryos [18]. The hippocampus and cortex were removed and incubated for 15 min in calcium and magnesium-free Hank's Balanced Saline Solution (Mediatech, Inc.) containing 0.25% trypsin. The cells were dissociated and plated into poly-D-Lysine-coated plastic or glass-bottom culture dishes containing Neurobasal Medium supplemented with 10% B27, 2 mM L-glutamine, and 25 µ M glutamate. Following cell attachment, the culture medium was replaced with medium without glutamate. Toxicity experiments were performed after 7 days in culture (7 DIC), a time during which neurons are vulnerable to excitotoxic and apoptotic insults [19, 20].

Quantification of neuron survival in hippocampal cell cultures [21] involved pre-marking microscope fields for the number of undamaged neurons, challenge of these cells with the excitotoxic agent, and monitoring the number of surviving cells over time. Neurons with intact neurites and a cell body that was smooth and round to oval in shape were considered viable, whereas neurons with beaded or fragmented neurites and a cell body that was shrunken and rough in appearance were considered nonviable. Overall cell viability was assessed by the release into the medium of lactate dehydrogenase assay (LDH kit, Roche), performed in a 96 well assay format. The LDH activities were normalized as the percentage of control of DMSO-treated control groups.

Measurement of Cellular ATP Levels

Neuronal cell ATP levels were assayed using a luciferin/luciferase-based assay. Neuronal cell cultures were rinsed with phosphate buffered saline and lysed with 0.2 ml lysis reagent (Roche, Mannheim, Germany). The ATP concentrations were quantified using the ATP Bioluminescence Assay Kit CLS II (Roche, Mannheim, Germany) with a Sirius-Luminometer (Berthold Detection Systems). Experimental values were compared to an ATP standard curve with values reported as nmole ATP per mg protein [22].

Rhodamine 123 Evaluation of Mitochondrial Membrane Potential and mtPTP Activation

Mitochondria from the forebrain (whole brain minus the cerebellum and brain stem) were isolated following euthanasia by cervical dislocation. The forebrains were homogenized with six hand strokes of a glass-Teflon dounce homogenizer containing 10 ml of isolation buffer (225 mM mannitol, 75 mM sucrose, 10 mM MOPS, 1 mM EGTA, 0.5% BSA, pH 7.2). The homogenate was then centrifuged for 5 min at 4°C at 1000 × g, the supernatant retained and centrifuged for 15 min at 4°C at 8000 × g, and the pellet resuspended in approximated 300 µl of isolation buffer. Protein was measured by pelleting the mitochondria in 4 µl aliquots, 2 min at 10000 × g, resuspending the pellet in 200 µl of isolation buffer without BSA by sonication and quantified using the Bradford method. Mitochondrial membrane potential and permeability transition were measured using the fluorescent probe rhodamine 123 [23] with a Perkin Elmer LS50B luminescent spectrophotometer set at 490 nm excitation and 535 nm emission with stirring. One mg of mitochondrial protein was added to 3 ml of reaction buffer (250 mM sucrose, 10 mM MOPS, 2 mM K2HPO4, 5 mM succinate, pH 7.2) at 30°C. Fluorescence was allowed to stabilized, and then CaCl2 was added in sequential aliquots of 15 or 25 nmol, each associated with a transient increase in fluorescence. Activation of the mtPTP, and collapse of the electrochemical gradient was signaled by the maximum rise and stabilization of fluorescence.

Rhodamine 123 concentrations were quantified using a standard curve, and membrane potentials were calculated by the Nernst equation with the concentration outside being measured directly by the minimum level of fluorescence after the addition of mitochondria (Foutside), and the concentration inside being the difference between the total concentration (maximum fluorescence obtained after CaCl2 addition, Ftotal) and the concentration outside. The mitochondrial volume was assumed to be 1 µl /µg [24].


Expression of Ant1 in Brain and Hippocampal Neurons

The regional distribution of Ant1 expression in the brain was determined by staining brain sections from heterozygous Ant1βgeo mice with X-gal to detect β-galactosidase transcribed from the endogenous Ant1 promoter. Ant1 was found to be expressed throughout the adult Ant1βgeo brain in both neurons and glial cells. It was highly expressed in the external and internal pyramidal neurons and in cortical layers III and V. Higher staining was seen in the reticular thalamic nucleus and lateral ventricles. Ant1 expression was also seen in the hippocampal pyramidal neurons (CA1, CA2, CA3 and hilus), but not in the granule cells in the dentate gyrus (Fig. 1A). However, the absence of β-galactosidase staining in the granule cells in the dentate gyrus is probably the result of suppression of expression of the βgeo fusion protein in these cells rather than lack of transcription from the Ant1 promoter [25]. Sagittal sections of cerebellum showed that Ant1 was highly expressed in the Purkinje and granule cell layers, and in the fastigal nuclei (Fig. 1B).

Fig. 1
Ant1 Expression in the Mouse Brain and Hippocampal Neurons

To confirm that neurons express Ant1, primary cultured hippocampal neurons differentiated from the embryonic brains of Ant1βgeo mice were stained with X-gal and found to be strongly positive. Moreover, the fusion protein was localized to the neuronal mitochondria, presumably targeted there by the first third of the Ant1 protein that was included in the fusion protein (Fig. 1C) [12].

Previously, we observed that Ant1 is up-regulated in response to cortical lesions resulting in glial scaring [26] and that this is mediated through TGFβ-Smad signal transduction pathway [27]. To determine if Ant1 is also inducible in neurons, we used Western blots to examine the levels of Ant1 and Ant2 in culture hippocampal neurons, following 24h exposure to 100 µM glutamate. After glutamate exposure, Ant1 increased in the neurons, but Ant2 levels were unaffected (Fig. 2A). This was also true for the whole brain since mice injected with the neuronal excitotoxin KA showed an increase in Ant1 protein, but not in Ant2 protein (Figure 2B).

Figure 2
Excitatory Challenge Induces Ant1 but not Ant2 Protein Levels in Cultured Neurons and Brains

Ant1-deficient Mice are More Resistant KA Induced Mortality

To determine if Ant1-deficiency affects the brain’s susceptibility to excitotoxic challenge, we injected age-matched Ant1-deficient and control mice with a single dose of KA and then monitored the seizure activity and mortality of the mice at 2 hours and then 48 hours. Two hours after injection, 90% of the Ant1-deficient (9 of 10) mice and 100% of the control mice exhibited stage 3 or above seizure activity (Table 1). However, 92% (11 of 12) of the control mice died, while only 40% (4 of 10) of the ANT1-deficient mice died, a significant difference (P < 0.01) (Table 1). This mortality difference was significant even when only mice showing stage 3 seizure activities or above were included in the analysis with 4/9 stage 3 Ant1-deficient mice versus 10/12 stage 3 control mice having died. By 48 hours post-injection an additional Ant1-deficient mouse had died, yet the difference in mortality was still significantly different, P < 0.02 (Chi Square) or P < 0.05 (Fisher Exact Test). Thus, Ant1-deficiency it is strongly protective of animal mortality following KA excitotoxicity, though Ant1-deficiency is not protective for KA-induced seizures‥

Table I
Seizure Activity and Mortality in Mice Two Hours After Systemic KA Administration.

Ant1-deficient Neurons are More Resistant to Glutamate-Induced Excitotoxicity

To examine the role of Ant1 in neuronal survival after excitotoxic challenge, we exposed cultured hippocampal and cortical neurons to increasing concentrations of glutamate. Glutamate binds to the NMDA receptor, resulting in the influx of Ca++ into the cells and leading to increased ROS production and excitotoxic cell death [28]. After 24 hours of 20 to 400 µM glutamate exposure, about twice as many of the Ant1-deficient hippocampal neurons survived as undamaged neurons in pre-marked microscopic fields as wild type neurons (Fig. 3A). This cell survival data was confirmed by cell lysis release of LDH into the medium (data not shown). Increased glutamate resistance was also seen in Ant1-deficient cortical neurons (Fig. 3B). Therefore, Ant1-deficient neurons are significantly more resistant to glutamate excitotoxicity than the wild type neurons, suggesting that the loss of Ant1 is neuroprotective.

Figure 3
Ant1-Deficiency Protects Cultured Hippocampal Neurons from Excitotoxic Death

Ant1-Deficient Neurons are More Resistant to DNA Damage-Induced Cell Death

To determine if Ant1-deficiency protected neurons to other initiators of cell death, we exposed cortical and hippocampal Ant1-deficient and wild type neurons to the topoisomerase II inhibitor, etoposide [29]. Cell lysis was quantified through the release of LDH into the medium after 24 hours. Following etoposide exposure, wild type cortical and hippocampal neurons released almost twice as much LDH as did the Ant1-deficient neurons (Figure 4). This etoposide-induced neuronal death was associated with PARP cleavage, detected using Western blots (data not shown). Thus, Ant1-deficient cells were more resistant to etoposide induced cell death than wild type neurons (Figure 4).

Figure 4
Ant1-Deficiency Protects Cultured Neurons from Death Induced by DNA Damage

Ant1-deficient Neurons have Reduced Intracellular ATP levels

To determine if Ant1-deficiency reduced cellular ATP levels, we used a luciferase assay to measure ATP concentrations in cell lysates. This revealed that the ATP levels were decreased by approximately 20% in the embryonic cortical neurons (p < 0.05) and 67% in hippocampal neurons (p < 0.001) derived from Ant1-deficient brains (Fig. 5). The residual levels of ATP sustained by the Ant1-deficient neurons probably reflect continued ADP -ATP exchange through Ant2 and ATP generation by glycoysis.

Figure 5
Lower Intracellular ATP Levels in Cortical and Hippocampal Neurons of ANT1-Deficient Mice

Ant1-deficient Neuronal Mitochondria are Resistant to Ca++-Induced mtPTP Opening

Mitochondria isolated from the brains of Ant1-deficient and wild type mice were assayed for the mitochondrial inner membrane electrochemical potential and sensitivity of the mtPTP to Ca++ activation, both monitored by the uptake and release of rhodamine 123 in energized mitochondria. Forebrain mitochondria from Ant1-deficient mice were found to have a membrane potential of 193 mV while wild type mitochondria had a membrane potential of 184 mV (Fig. 6A). This approximately 9 mV/mg protein increase in mitochondrial inner membrane potential is highly significant and may reflect a reduction in the proton leak through the inner membrane due to loss of the Ant1 [30].

Fig. 6
Monitoring Membrane Potential and mtPTP Transition in Response to Ca++ Additions and mtPTP Transition

To measure the potential of the Ant1-deficient mtPTP to undergo permeability transition, the amount of Ca++ was quantified that was required to cause an irreversible release of rhodamine 123 from the mitochondria due to the collapse of the electrochemical gradient (Figure 6B). The Ant1-deficient mitochondria required 72 nmole of Ca++ to initiate mtPTP transition while wild type mitochondria required 60 nmoles, approximately 20% less (P < 0.05) (Figure 6C). Hence the mtPTPs of the Ant1-deficient mitochondria are significantly more resistant to Ca++-induced permeability transition. Still, the increased resistance of the partially Ant1-deficient brain mitochondria (Ant1 null, Ant2 positive) to Ca++ induced permeability transition was much less than that required to activate the completely Ant1-deficient liver mitochondria (Ant1 null, Ant2 null) [11], suggesting that both Ant1 and Ant2 may contribute to the Ca++ sensitivity of the mtPTP.


We had previously shown that Ant1 is strongly expressed in mouse skeletal muscle, heart, and brain [5, 12]; and have now determined the regional expression of Ant1 in the brain and confirmed that Ant1 is strongly expressed in neurons. Even so, while inactivation of Ant1 in mouse [12] and ANT1 in humans [31] results in severe muscle and heart pathology, neither mice of humans show an overt neurological phenotype. This is particularly remarkable since Ant1-deficiency in the mouse cortical and hippocampal neurons results in a 1/5 and 2/3 reduction in ATP levels, respectively. This reduction in cellular ATP levels is not a product of reduced OXPHOS coupling, since the mitochondrial inner membrane potential of Ant1-deficient mitochondria is significantly higher than that found in wild type mitochondria, a result consistent with our previous observation that Ant1 makes a significant contribution to the mitochondrial inner membrane basal proton leak which inactivation Ant1 blocks [30].

The Ant1-deficient mouse is also significantly more resistant to KA-induced neuronal excitotoxicity and death than wild type mice, and Ant1-deficient cortical and hippocampal neurons are more resistance to glutamate and KA induced excititoxic cell death as well as etoposide-induced cell death. Isolated Ant1-deficient brain mitochondria are also significantly more resistance to Ca++ induced mtPTP permeability transition than controls [21, 3235]. Since both etoposide-induced cell death and Ca++-induced permeability transition of cultured rodent embryonic neurons has been shown to be inhibited by cyclosporin A [36] and ectoposide induced cell death shown to be associated with increased cell reactivity to annexin V [36], it would seem that Ant1 is important in excitotoxic Ca++-induced mtPTP permeability transition leading to cell death by apoptosis.

These observations lead to the question, why are Ant1-deficient brains resistance to excitotoxic insult? We have previously shown that Ant1, but not Ant2, is induced by brain trauma, medicated by TGFβ and the Smad pathway [26, 27]. Furthermore, it has been reported that increased expression of Ant1 achieved by transfection of cultured cells is pro-apoptotic [37]. Therefore, we might hypothesize that Ant1 is bi-functional in the brain. Under normal circumstances, Ant1 functions to export mitochondrial ATP into the nucleus-cytsol compartment. When the brain is stressed, TGFβ and the Smads are activated, inducing Ant1 to transport out more mitochondrial ATP to the nuclear-cytosol to facilitate repair and recovery. However, if the damage to the cell is sufficient to compromise mitochondrial ATP production, then induction of Ant1 can not increase ATP levels and does not resolve the cellular problem. Since the accumulation of such energetically defective cells would erode organ function, the continued induction of Ant1 ultimately activates the mtPTP, resulting in the elimination of the defective cell by apoptosis. While this is an optimal strategy at the individual cell level, generalized brain insults such as those resulting from KA excitotoxicity or ischemic stroke can result in pan-neuronal apoptosis, causing destruction of the brain function and death. Inactivation of Ant1 or inhibition of the mtPTP [38] may then block this catastrophic outcome.


This work was supported by NIH grants NS41650, AG13154, NS21325, AG24373 and HL64017 awarded to DCW.


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


1. Brown MD, Wallace DC. Molecular basis of mitochondrial DNA disease. Journal of Bioenergetics and Biomembranes. 1994;26:273–289. [PubMed]
2. Li K, Warner CK, Hodge JA, Minoshima S, Kudoh J, Fukuyama R, Maekawa M, Shimizu Y, Shimizu N, Wallace DC. A human muscle adenine nucleotide translocator gene has four exons, is located on chromosome 4, and is differentially expressed. Journal of Biological Chemistry. 1989;264:13998–14004. [PubMed]
3. Stepien G, Torroni A, Chung AB, Hodge JA, Wallace DC. Differential expression of adenine nucleotide translocator isoforms in mammalian tissues and during muscle cell differentiation. Journal of Biological Chemistry. 1992;267:14592–14597. [PubMed]
4. Dolce V, Scarcia P, Iacopetta D, Palmieri F. A fourth ADP/ATP carrier isoform in man: identification, bacterial expression, functional characterization and tissue distribution. FEBS Letters. 2005;579:633–637. [PubMed]
5. Levy SE, Chen Y, Graham BH, Wallace DC. Expression and sequence analysis of the mouse adenine nucleotide translocase 1 and 2 genes. Gene. 2000;254:57–66. [PubMed]
6. Rodic N, Oka M, Hamazaki T, Murawski MR, Jorgensen M, Maatouk DM, Resnick JL, Li E, Terada N. DNA methylation is required for silencing of ant4, an adenine nucleotide translocase selectively expressed in mouse embryonic stem cells and germ cells. Stem Cells. 2005;23:1314–1323. [PubMed]
7. Dorner A, Schultheiss HP. Adenine nucleotide translocase in the focus of cardiovascular diseases. Trends in Cardiovascular Medicine. 2007;17:284–290. [PubMed]
8. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochimica et Biophysica Acta. 1995;1241:139–176. [PubMed]
9. Marzo I, Brenner C, Zamzami N, Jurgensmeier JM, Susin SA, Vieira HL, Prevost MC, Xie Z, Matsuyama S, Reed JC, Kroemer G. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science. 1998;281:2027–2031. [PubMed]
10. Belzacq AS, Vieira HL, Kroemer G, Brenner C. The adenine nucleotide translocator in apoptosis. Biochimie. 2002;84:167–176. [PubMed]
11. Kokoszka JE, Waymire KG, Levy SE, Sligh JE, Cai J, Jones DP, MacGregor GR, Wallace DC. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature. 2004;427:461–465. [PMC free article] [PubMed]
12. Graham BH, Waymire KG, Cottrell B, Trounce IA, MacGregor GR, Wallace DC. A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/skeletal muscle isoform of the adenine nucleotide translocator. Nature Genetics. 1997;16:226–234. [PubMed]
13. Murdock D, Boone BE, Esposito LA, Wallace DC. Up-regulation of nuclear and mitochondrial genes in the skeletal muscle of mice lacking the heart/muscle isoform of the adenine nucleotide translocator. Journal of Biological Chemistry. 1999;274:14429–14433. [PubMed]
14. Esposito LA, Kokoszka JE, Waymire KG, Cottrell B, MacGregor GR, Wallace DC. Mitochondrial oxidative stress in mice lacking the glutathione peroxidase-1 gene. Free Radical Biology and Medicine. 2000;28:754–766. [PMC free article] [PubMed]
15. Subramaniam V, Golik P, Murdock DG, Levy S, Kerstann KW, Coskun PE, Melkonian GA, Wallace DC. MITOCHIP assessment of differential gene expression in the skeletal muscle of Ant1 knockout mice: coordinate regulation of OXPHOS, antioxidant, and apoptotic genes. Biochimica et Biophysica Acta. 2008;1777:666–675. [PMC free article] [PubMed]
16. MacGregor GR, Zambrowicz BP, Soriano P. Tissue non-specific alkaline phosphatase is expressed in both embryonic and extraembryonic lineages during mouse embryogenesis but is not required for migration of primordial germ cells. Development. 1995;121:1487–1496. [PubMed]
17. Schauwecker PE. Differences in ionotropic glutamate receptor subunit expression are not responsible for strain-dependent susceptibility to excitotoxin-induced injury. Brain Research. Molecular Brain Research. 2003;112:70–81. [PubMed]
18. Pang Z, Geddes JW. Mechanisms of cell death induced by the mitochondrial toxin 3-nitropropionic acid: acute excitotoxic necrosis and delayed apoptosis. Journal of Neuroscience. 1997;17:3064–3073. [PubMed]
19. Mattson MP, Wang H, Michaelis EK. Developmental expression, compartmentalization, and possible role in excitotoxicity of a putative NMDA receptor protein in cultured hippocampal neurons. Brain Research. 1991;565:94–108. [PubMed]
20. Mattson MP, Goodman Y, Luo H, Fu W, Furukawa K. Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. Journal of Neuroscience Research. 1997;49:681–697. [PubMed]
21. Mattson MP, Barger SW, Begley JG, Mark RJ. Calcium, free radicals, and excitotoxic neuronal death in primary cell culture. Methods in Cell Biology. 1995;46:187–216. [PubMed]
22. Lee J, Chan SL, Lu C, Lane MA, Mattson MP. Phenformin suppresses calcium responses to glutamate and protects hippocampal neurons against excitotoxicity. Experimental Neurology. 2002;175:161–167. [PubMed]
23. Scaduto RC, Jr, Grotyohann LW. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophysical Journal. 1999;76:469–477. [PubMed]
24. Baracca A, Sgarbi G, Solaini G, Lenaz G. Rhodamine 123 as a probe of mitochondrial membrane potential: evaluation of proton flux through F(0) during ATP synthesis. Biochimica et Biophysica Acta. 2003;1606:137–146. [PubMed]
25. Campbell PK, Waymire KG, Heier RL, Sharer C, Day DE, Reimann H, Jaje JM, Friedrich GA, Burmeister M, Bartness TJ, Russell LD, Young LJ, Zimmer M, Jenne DE, MacGregor GR. Mutation of a novel gene results in abnormal development of spermatid flagella, loss of intermale aggression and reduced body fat in mice. Genetics. 2002;162:307–320. [PubMed]
26. Buck CR, Jurynec MJ, Gupta DK, Law AK, Bilger J, Wallace DC, McKeon RJ. Increased adenine nucleotide translocator 1 in reactive astrocytes facilitates glutamate transport. Experimental Neurology. 2003;181:149–158. [PMC free article] [PubMed]
27. Law AK, Gupta D, Levy S, Wallace DC, McKeon RJ, Buck CR. TGF-beta1 induction of the adenine nucleotide translocator 1 in astrocytes occurs through Smads and Sp1 transcription factors. BMC Neuroscience. 2004;5:1. [PMC free article] [PubMed]
28. Mattson MP, Pedersen WA, Duan W, Culmsee C, Camandola S. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Annals of the New York Academy of Sciences. 1999;893:154–175. [PubMed]
29. Capranico G, Giaccone G, D'Incalci M. DNA topoisomerase II poisons and inhibitors. Cancer Chemotherapy and Biological Response Modifiers. 1999;18:125–143. [PubMed]
30. Brand MD, Pakay JL, Ocloo A, Kokoszka J, Wallace DC, Brookes PS, Cornwall EJ. The basal proton conductance of mitochondria depends on adenine nucleotide translocase content. Biochemical Journal. 2005;392:353–362. [PubMed]
31. Palmieri L, Alberio S, Pisano I, Lodi T, Meznaric-Petrusa M, Zidar J, Santoro A, Scarcia P, Fontanesi F, Lamantea E, Ferrero I, Zeviani M. Complete loss-of-function of the heart/muscle-specific adenine nucleotide translocator is associated with mitochondrial myopathy and cardiomyopathy. Human Molecular Genetics. 2005;14:3079–3088. [PubMed]
32. Lafon-Cazal M, Pietri S, Culcasi M, Bockaert J. NMDA-dependent superoxide production and neurotoxicity. Nature. 1993;364:535–537. [PubMed]
33. Zhang Y, Tatsuno T, Carney JM, Mattson MP. Basic FGF, NGF, and IGFs protect hippocampal and cortical neurons against iron-induced degeneration. Journal of Cerebral Blood Flow and Metabolism. 1993;13:378–388. [PubMed]
34. Dugan LL, Sensi SL, Canzoniero LM, Handran SD, Rothman SM, Lin TS, Goldberg MP, Choi DW. Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. Journal of Neuroscience. 1995;15:6377–6388. [PubMed]
35. Reynolds IJ, Hastings TG. Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. Journal of Neuroscience. 1995;15:3318–3327. [PubMed]
36. El-Mir MY, Detaille D, G RV, Delgado-Esteban M, Guigas B, Attia S, Fontaine E, Almeida A, Leverve X. Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. Journal of Molecular Neuroscience. 2008;34:77–87. [PubMed]
37. Bauer MK, Schubert A, Rocks O, Grimm S. Adenine nucleotide translocase-1, a component of the permeability transition pore, can dominantly induce apoptosis. Journal of Cell Biology. 1999;147:1493–1502. [PMC free article] [PubMed]
38. Merlini L, Angelin A, Tiepolo T, Braghetta P, Sabatelli P, Zamparelli A, Ferlini A, Maraldi NM, Bonaldo P, Bernardi P. Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathies. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:5225–5229. [PubMed]